Preview

Rheumatology Science and Practice

Advanced search

THE CLINICAL SIGNIFICANCE OF MATRIX METALLOPROTEINASES IN RHEUMATOID ARTHRITIS PATIENTS (REVIEW OF THE LITERATURE AND OUR OWN DATA)

https://doi.org/10.14412/1995-4484-2014-79-84

Abstract

Matrix metalloproteinases (MMPs) are a group of over 20 proteolytic enzymes responsible for cleavage of protein components of the extracellular matrix. Three types of MMPs play an important role in the development of joint damage in patients with rheumatoid arthritis (RA): collagenases (MMP1, 8 and 13), stromelysins (MMP3), and gelatinases (MMP9). MMP3 is considered to be one of the key mediators of joint damage. Increased serum level of MMP is not specific for RA and may be registered in other rheumatic diseases (osteoarthritis, psoriatic arthritis, gout, ankylosing spondylitis, systemic lupus erythematosus); however, monitoring of the level of MMP is of particular clinical importance in patients with RA. MMP3 serum level may be a useful marker of disease activity. Several studies have shown a correlation of MMP3 concentration with clinical and laboratorial parameters of inflammatory activity (ESR and C-reactive protein – CRP) in RA patients. The elevated level of MMP3 is associated with radiological changes in joints and can also be a predictor of severe destructive lesions in RA patients. Evaluation of the MMP3 level can also be useful for monitoring the therapy effectiveness using both standard disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (GEBD). Thus, evaluation of MMP3 concentration is useful for assessing disease activity and efficacy of treatment with DMARDs and GEBD, as well as for predicting the severity of destructive changes in joints.

About the Authors

Anastasiya S Avdeeva
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation


E N Aleksandrova
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation


E L Nasonov
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation


References

1. <div><p>Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290–331. [Nasonov EL, Karateev DE, Balabanova RM. Revmatoidnyi artrit. Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo. Moscow: GEOTAR-Media; 2008. P. 290–331.]</p><p>McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–42. DOI: http://dx.doi.org/10.1038/nri2094.</p><p>Burrage P, Mix K, Brinckerhoff C. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529–43. DOI: http://dx.doi.org/10.2741/1817.</p><p>Murphy G, Knauper V, Atkinson S, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002;4(Suppl 3):39–49. DOI: http://dx.doi.org/10.1186/ar572.</p><p>Flannery C. MMPs and ADAMTSs: functional studies. Front Biosci. 2006;11:544–69. DOI: http://dx.doi.org/10.2741/1818.</p><p>Ribbens C, Andre B, Kaye O, et al. Synovial fluid matrix metalloproteinase 3 levels are increased in inflammatory arthritis whether erosive or not. Rheumatology (Oxford). 2000;39(12):1357–65. DOI: http://dx.doi.org/10.1093/rheumatology/39.12.1357.</p><p>Ronday HK, Smits HH, Van Muijen GN, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1996;35(5):416–23. DOI: http://dx.doi.org/10.1093/rheumatology/35.5.416.</p><p>Bonassar L, Frank E, Murray J, et al. Grodzinsky: Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum. 1995;38(2):173–83. DOI: http://dx.doi.org/10.1002/art.1780380205.</p><p>Unemori E, Bair M, Bauer E, et al. Amento: Stromelysin expression regulates collagenase activation in human fibroblasts. Dissociable control of two metalloproteinases by interferon-gamma. J Biol Chem. 1991;266(34):23477–82.</p><p>Sasaki S, Iwata H, Ishiguro N, et al. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol. 1994;13(2):228–333.</p><p>Keyszer G, Lambiri I, Nagel R, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-l complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol. 1999;26(2):251–8.</p><p>Posthumus MD, Limburg PC, Westra J, et al. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol. 2000;27(12):2761–8.</p><p>Green M, Gough A, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2003;42(1):83–8. DOI: http://dx.doi.org/10.1093/rheumatology/keg037.</p><p>So A, Chamot AM, Peclat V, Gerster JC. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatololy (Oxford). 1999;38(5):407–10. DOI: http://dx.doi.org/10.1093/rheumatology/38.5.407.</p><p>Ally M, Hodkinson B, Meyer P, et al. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm. 2013;2013:183653. DOI: 10.1155/2013/183653.</p><p>Kobayashi A, Naito S, Enomoto H, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 2007;131(4):563–70.</p><p>Syversen SW, Haavardsholm E, Boyesen P, et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with infl ammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis. 2010;69(5):845–50. DOI: 10.1136/ard.2009.122325. Epub 2010 Mar 16.</p><p>Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43(3):852–8. DOI: http://dx.doi.org/10.1002/1529-0131(200004)43:4%3C852::AID-ANR16%3E3.0.CO;2-7.</p><p>Fujikawa K, Kawakami A, Tamai M, et al. High serum cartilage oligomeric matrix protein Determines the subset of patients with early-stage Rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J Rheumatol. 2009;36(6):1126–9. DOI: 10.3899/jrheum.080926. Epub 2009 May 15..</p><p>Tchetverikov I, Lard LR, DeGroot J, et al. Matrix metalloproteinases-3, -8, -9 as markers o f disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis. 2003;62(11):1094–9. DOI: http://dx.doi.org/10.1136/ard.62.11.1094.</p><p>Young-Min S, Cawston T, Marshall N, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum. 2007;56(10):3236–47. DOI: http://dx.doi.org/10.1002/art.22923.</p><p>Houseman M, Potter C, Marshall N, et al. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther. 2012;14:R30. DOI: http://dx.doi.org/10.1186/ar3734.</p><p>Mamehara A, Sugimoto T, Sudiyama D, et al. Serum matrix Metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatiс drugs. Kobe J Med Sci. 2010;56(3):E98–107.</p><p>Posthumus M, Limburg P, Westra J, et al. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. J Rheumatol. 2002;29(5):883–9.</p><p>Garnero P, Thompson E, Woodworth T, Smolen J. Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum. 2010;62(1):33–43. DOI: 10.1002/art.25053.</p><p>Yokoe I, Nishio S, Sato H, Kobayashi H. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol. 2011;21(6):710–4. DOI: 10.1007/s10165-011-0474-z. Epub 2011 Jun 8.</p><p>Visvanathan S, Wagner C, Marini J, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24. DOI: 10.1186/1546-0096-8-24.</p><p>Doyle M, Rahman M, Frederick B, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford). 2013;52(7):1214–9. DOI: 10.1093/rheumatology/kes381. Epub 2013 Feb 14.</p><p>Urata Y, Uesato R, Tanaka D, et al. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis. 2012;71(4):534–40. DOI: 10.1136/annrheumdis-2011-200108. Epub 2011 Oct 21.</p><p>Visvanathan S, Marini J, Smolen J, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol. 2007;34:1465–74.</p><p>Nishimoto N. Drug free remission after cessation of Actemra monotherapy (DREAM study). Ann Rheum Dis. 2010;69(Suppl 3):98.</p><p>Kaneko A, Kida D, Saito K, et al. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatology Int. 2012 Nov;32(11):3631–7. DOI: 10.1007/s00296-011-2256-5.</p><p>Авдеева АС, Александрова ЕН, Панасюк ЕЮ и др. Динамика рентгенологического прогрессирования и уровня матриксной металлопротеиназы 3 (ММР 3) у больных РА на фоне терапии тоцилизумабом (ТЦЗ). Сборник тезисов VII Всероссийской конференции «Ревматология в реальной клинической практике». Владимир; 2012. 5. [Avdeeva AS, Aleksandrova EN, Panasyuk EYu, et al. Dinamika rentgenologicheskogo progressirovaniya i urovnya matriksnoi metalloproteinazy 3 (MMR 3) u bol'nykh RA na fone terapii totsilizumabom (TTsZ). Sbornik tezisov VII Vserossiiskoi konferentsii «Revmatologiya v real'noi klinicheskoi praktike». Vladimir; 2012. 5.]</p><p>Авдеева АС, Александрова ЕН, Новиков АА и др. Взаимосвязь клинической эффективности терапии тоцилизумабом с уровнем матриксной металлопротеиназы-3 в сыворотке крови у больных ревматоидным артритом. Терапевтический архив. 2013;5:24–9. [Avdeeva AS, Aleksandrova EN, Novikov AA, et al. Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Terapevticheskii arkhiv. 2013;85(5):24–9.]</p><p>Панасюк ЕЮ, Авдеева АС, Александрова ЕН и др. Опыт применения тоцилизумаба у больных ревматоидным артритом в России: исследование ЛОРНЕТ. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-Пресс; 2013. С. 270–377. [Panasyuk EYu, Avdeeva AS, Aleksandrova EN, et al. Opyt primeneniya totsilizumaba u bol'nykh revmatoidnym artritom v Rossii: issledovanie LORNET. Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Moscow: IMA-Press; 2013. P. 270–377.]</p><p>Авдеева АС, Александрова ЕН, Новиков АА и др. Взаимосвязь уровня антител к цитруллинированным белкам, активности заболевания и маркеров деструкции костной и хрящевой ткани при ревматоидном артрите. Клиническая лабораторная диагностика. 2013;(9):15–6. [Avdeeva AS, Aleksandrova EN, Novikov AA, et al. Vzaimosvyaz' urovnya antitel k tsitrullinirovannym belkam, aktivnosti zabolevaniya i markerov destruktsii kostnoi i khryashchevoi tkani pri revmatoidnom artrite. Klinicheskaya laboratornaya diagnostika. 2013;(9):15–6.]</p></div><br />


Review

For citations:


Avdeeva A.S., Aleksandrova E.N., Nasonov E.L. THE CLINICAL SIGNIFICANCE OF MATRIX METALLOPROTEINASES IN RHEUMATOID ARTHRITIS PATIENTS (REVIEW OF THE LITERATURE AND OUR OWN DATA). Rheumatology Science and Practice. 2014;52(1):79-84. (In Russ.) https://doi.org/10.14412/1995-4484-2014-79-84

Views: 2527


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)